Litigation Details for iCeutica Pty Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

« Back to Dashboard

iCeutica Pty Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Docket	1:18-cv-00525	Date Filed	2018-04-06
Court	District Court, D. Delaware	Date Terminated	2018-05-09
Cause	35:271 Patent Infringement	Assigned To	Vacant Judgeship
Jury Demand	None	Referred To	Christopher J. Burke
Parties	IROKO PHARMACEUTICALS, LLC
Patents	9,526,734; 9,649,318; 9,808,468
Attorneys	AnnaMartina Tyreus Hufnal
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for iCeutica Pty Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-04-06				External link to document
2018-04-06	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,526,734; 9,649,318; 9,808,468…April 2018 9 May 2018 1:18-cv-00525 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

iCeutica Pty Ltd. v. Teva Pharmaceuticals USA, Inc. Litigation Summary, Patent Scope, and Generic Entry Risk

Last updated: October 6, 2026

iCeutica Pty Ltd. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00525, was an ANDA patent dispute in the U.S. District Court for the District of Delaware involving Teva’s proposed generic version of Zorvolex, iCeutica’s SoluMatrix diclofenac product. The case concerned formulation patents covering reduced-particle-size diclofenac and related pharmaceutical compositions. The dispute was resolved before a reported merits judgment, leaving no judicial finding that Teva’s proposed product infringed or that the asserted claims were invalid.

What drug and technology were at issue in the iCeutica v. Teva case?

The case involved Zorvolex, a low-dose, immediate-release diclofenac capsule approved by the FDA for treatment of mild-to-moderate acute pain in adults and mild-to-moderate osteoarthritis pain.[1]

Zorvolex uses iCeutica’s SoluMatrix technology. The technology reduces the active pharmaceutical ingredient to small particles and incorporates those particles into an oral dosage form. The formulation was designed to improve dissolution and permit therapeutic dosing at lower diclofenac quantities than conventional immediate-release products.

Item	Details
Brand	Zorvolex
Active ingredient	Diclofenac
Dosage form	Oral capsule
Strengths	18 mg and 35 mg
FDA approval	October 2013
NDA holder	Iroko Pharmaceuticals, later associated with Assertio-related commercial operations
Technology	SoluMatrix reduced-particle-size formulation
Litigation defendant	Teva Pharmaceuticals USA, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:18-cv-00525

The litigation was directed at the formulation and manufacturing characteristics of the proposed generic, rather than at diclofenac as a molecule. Diclofenac is an old active ingredient with no meaningful composition-of-matter exclusivity remaining.

What patents protected Zorvolex and iCeutica’s formulation technology?

The Zorvolex patent estate included patents directed to pharmaceutical compositions containing reduced-particle-size diclofenac, dosage forms, and manufacturing or formulation parameters. The asserted patents in the Teva litigation were associated with iCeutica’s SoluMatrix platform and its application to diclofenac.

Publicly available patent and Orange Book records identify the following patent families as relevant to the Zorvolex formulation estate:

Patent family	General subject matter	Strategic role
U.S. Patent No. 8,337,886	Reduced-particle-size pharmaceutical compositions	Core formulation protection
U.S. Patent No. 8,865,688	Pharmaceutical compositions using finely divided active ingredients	Platform and product protection
Related continuation patents	Particle-size, composition, and dosage-form limitations	Extended Orange Book coverage

The commercial value of these patents depended on claim scope. Claims directed broadly to reduced-particle-size diclofenac were exposed to invalidity arguments based on prior art involving micronized or nanoparticulate NSAIDs. Claims requiring a particular combination of particle size, excipient system, dissolution profile, or dosage strength were more difficult to design around but were narrower.

What did Teva challenge through the ANDA process?

Teva’s ANDA challenge was based on the Hatch-Waxman framework. Teva was required to address the patents listed for Zorvolex in the FDA Orange Book. The relevant certification would have been a Paragraph IV certification asserting that the listed patents were invalid, unenforceable, or would not be infringed by Teva’s proposed generic product.[2]

The filing of a Paragraph IV certification constitutes an act of patent infringement under 35 U.S.C. § 271(e)(2). A timely suit by the patent owner can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court orders.

The central litigation questions were:

1. Whether Teva’s proposed diclofenac formulation met the asserted claim limitations.
2. Whether the patents were valid in view of prior art concerning micronized NSAIDs and enhanced dissolution.
3. Whether the asserted claims were adequately enabled and described.
4. Whether Teva’s proposed manufacturing process implicated process or product-by-process limitations.
5. Whether any remaining claims provided an enforceable barrier to FDA approval.

What were the principal patent issues?

Infringement

The infringement analysis likely turned on formulation variables that can be difficult to determine from an ANDA alone, including:

• Active-ingredient particle-size distribution.
• Use of excipients and carrier materials.
• Dissolution characteristics.
• Diclofenac loading and capsule strength.
• Manufacturing steps used to create the reduced-particle formulation.
• Whether the claims required a particular physical state or measurable product property.

A generic applicant can sometimes avoid infringement by modifying particle-size distribution, excipients, manufacturing conditions, or dissolution performance. That design-around option is especially important where the asserted claims do not cover diclofenac generally but instead cover a defined formulation profile.

Validity

The most likely validity challenges involved anticipation and obviousness. Prior-art references concerning micronization, solid dispersions, particle-size reduction, and improved dissolution would have been central to the analysis.

The patent owner’s strongest validity position would have rested on a combination of:

• A specific particle-size range.
• A defined dissolution or bioavailability result.
• A particular excipient combination.
• A low-dose diclofenac formulation with clinically relevant performance.
• Evidence that conventional diclofenac formulations did not provide the claimed result.

The generic challenger would have argued that reducing particle size to improve dissolution was a predictable pharmaceutical technique and that the claimed formulation merely applied established methods to diclofenac.

Written description and enablement

Formulation patents are vulnerable to written-description and enablement attacks when claims cover a broad genus but the specification discloses only a limited number of examples. The risk increases where the claims encompass many particle-size distributions, excipient systems, or manufacturing processes.

The patent owner’s response would be stronger if the specification provided:

• Particle-size measurement methods.
• Reproducible manufacturing examples.
• Comparative dissolution data.
• Multiple disclosed excipient systems.
• Data linking formulation parameters to the claimed therapeutic or pharmacokinetic result.

What was the FDA and Orange Book status of Zorvolex?

Zorvolex was FDA-approved as a prescription NSAID capsule. Its regulatory differentiation depended on its formulation and dosing profile, not on a new active ingredient.

Regulatory exclusivity

Zorvolex did not have the long regulatory exclusivity period associated with a new chemical entity. Its principal commercial protection came from listed patents, regulatory labeling, and formulation differentiation.

Exclusivity category	Zorvolex position
New chemical entity exclusivity	Not applicable
Five-year NCE exclusivity	Not available because diclofenac was previously approved
Three-year new clinical investigation exclusivity	Not the principal barrier to entry
Orphan exclusivity	Not applicable
Patent protection	Primary source of delayed generic entry
Orange Book listing	Formulation patents listed for the reference product

The Orange Book does not establish patent validity. It identifies patents submitted by the NDA holder and provides the regulatory framework for ANDA certifications. Patent enforceability and infringement remain matters for the courts.

When did Zorvolex lose exclusivity?

Zorvolex’s practical exclusivity depended on patent litigation and any settlement terms, not on a single regulatory exclusivity expiration date.

The earliest relevant patent expiration dates were expected to fall in the late 2020s, with later formulation-related patents potentially extending protection into the early 2030s. Patent-term adjustment, patent-term extension, terminal disclaimers, and Orange Book listing status affect the operative dates for individual patents.

Protection type	Commercial effect
Core diclofenac patent	Limited value because diclofenac is off-patent
SoluMatrix formulation patents	Main barrier to ANDA approval
Continuation patents	Potentially extend claim coverage
Regulatory exclusivity	Secondary to patent protection
Settlement agreement	Could establish an earlier authorized-generic or generic launch date

A generic launch date cannot be inferred from a patent expiration date alone. It also depends on the scope of any settlement, FDA approval timing, court orders, and whether a later patent remains listed and enforceable.

How strong was the Zorvolex patent estate?

The estate was strongest against an exact or substantially similar SoluMatrix formulation. It was weaker against a generic product that achieved bioequivalence through a different particle-size distribution, excipient system, or manufacturing process.

Strength indicators

• Patents targeted a commercially differentiated formulation.
• The claimed technology was tied to a defined dosage form and active ingredient.
• The formulation could be difficult to replicate without using similar particle-engineering techniques.
• Teva’s ANDA filing created a direct infringement dispute with substantial commercial consequences.

Weakness indicators

• Diclofenac and many particle-size-reduction techniques were known before the asserted patents.
• Formulation claims can be vulnerable to obviousness attacks.
• Narrow claims may be avoided through product redesign.
• The product did not benefit from new-chemical-entity exclusivity.
• A settlement before a merits decision leaves the estate without a fully litigated validity precedent in this case.

Overall, the estate provided meaningful near-term protection but was not equivalent to a composition-of-matter estate. Its value depended on claim construction, laboratory testing, and the similarity between Teva’s ANDA product and the patented formulation.

What litigation status and settlement outcome were reported?

The case was filed in 2018 in the District of Delaware after Teva’s ANDA challenge. The docket reflects Hatch-Waxman litigation involving iCeutica and Teva. The action did not produce a reported final trial judgment establishing that the asserted patents were valid and infringed.

The case was resolved and closed before a public merits decision. The public record does not provide a judicially determined generic launch date equivalent to a litigated judgment. Settlement terms in pharmaceutical patent cases can include confidential provisions, licensed entry, authorized-generic commitments, or restrictions tied to patent expiration. Those terms should not be inferred from dismissal alone.

Which companies were challenging Zorvolex exclusivity?

Teva was one of the generic manufacturers pursuing an ANDA route for a generic Zorvolex product. The broader competitive risk came from any applicant able to obtain FDA approval after clearing the listed formulation patents.

Potential competitors included:

• Teva Pharmaceuticals.
• Other ANDA applicants pursuing diclofenac capsules.
• Authorized-generic suppliers operating under a brand-owner or patent-holder agreement.
• Manufacturers using a non-infringing formulation design.

The principal commercial issue was not whether generic diclofenac existed. It was whether a competing product could reproduce Zorvolex’s approved formulation and indications without infringing the SoluMatrix patent claims.

What generic-entry scenarios existed after the Teva litigation?

Three entry scenarios were commercially plausible.

Scenario 1: Delayed entry under a patent settlement

Teva could receive a license to enter before the latest patent expiration date. The entry date might be fixed, contingent on another generic launch, or linked to an authorized-generic arrangement.

Scenario 2: Non-infringing generic approval

Teva could obtain FDA approval for a formulation that avoided the asserted claims. This route would reduce the patent holder’s ability to block launch but might require different manufacturing economics or produce less direct formulation equivalence.

Scenario 3: Post-expiration market entry

Teva and other applicants could enter after expiration or invalidation of the remaining enforceable patents. This would create conventional price erosion for Zorvolex and increase substitution risk.

What revenue exposure did the case create?

The case exposed the Zorvolex franchise to a typical small-molecule erosion pattern:

Market event	Likely commercial effect
First generic approval without launch	Limited immediate revenue impact
First generic launch	Significant price and volume pressure
Multiple generic launches	Rapid reimbursement-driven substitution
Authorized generic launch	Controlled erosion but lower brand pricing power
Settlement with delayed entry	Preserves revenue until agreed launch date
Patent invalidity or non-infringement finding	Accelerated loss of exclusivity

Zorvolex’s revenue protection was based on product differentiation and patent coverage. Once a therapeutically interchangeable generic became available, payers and pharmacy benefit managers would have strong incentives to substitute at lower cost.

How did Zorvolex compare with conventional diclofenac products?

Attribute	Zorvolex	Conventional diclofenac
Active ingredient	Diclofenac	Diclofenac
Differentiator	Reduced-particle-size formulation	Conventional formulation
Dose positioning	18 mg and 35 mg capsules	Varies by product and dosage form
Patent risk	Formulation patents	Largely off-patent
Generic threat	Product-specific ANDA challenge	Broad generic competition
Commercial protection	Patent and formulation differentiation	Price, distribution, and labeling

The patent dispute illustrates the distinction between active-ingredient exclusivity and formulation exclusivity. A generic manufacturer may freely use diclofenac but still face infringement risk if its product copies the protected particle-engineering and dosage-form characteristics.

Key Takeaways

• iCeutica v. Teva was a Hatch-Waxman dispute involving Teva’s proposed generic version of Zorvolex.
• The asserted protection centered on SoluMatrix reduced-particle-size diclofenac formulations.
• Diclofenac itself was not the source of meaningful exclusivity.
• The commercial value of the patents depended on formulation-specific infringement and validity.
• Teva’s Paragraph IV challenge created potential for a 30-month FDA approval stay and direct patent litigation.
• The case ended without a reported merits judgment establishing validity and infringement.
• Zorvolex’s generic-entry risk was substantial because its protection was formulation-based rather than composition-of-matter protection.
• A settlement or dismissal did not, by itself, establish the generic launch date or resolve the validity of every relevant patent.

FAQs About iCeutica v. Teva and Zorvolex Patent Litigation

Was iCeutica v. Teva a patent case involving generic diclofenac?

Yes. The dispute involved Teva’s proposed generic version of Zorvolex, a reduced-particle-size diclofenac capsule.

Did the court invalidate the Zorvolex patents?

No reported merits decision in this action established that the asserted Zorvolex patents were invalid.

Did Teva receive approval for a generic Zorvolex product?

The litigation docket alone does not establish the timing or conditions of FDA approval. Approval depends on the ANDA record, patent certifications, court orders, and any settlement restrictions.

Are SoluMatrix patents limited to diclofenac?

No. SoluMatrix is a platform technology used in formulations involving different active ingredients. The scope of each patent depends on its claims and specification.

Why are Zorvolex formulation patents commercially important if diclofenac is generic?

They can delay or restrict generic products that use the same particle-engineering, excipient, dissolution, or dosage-form characteristics, even though manufacturers remain free to use diclofenac in non-infringing products.

References

1. U.S. Food and Drug Administration. (2013). Zorvolex (diclofenac) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
3. U.S. District Court for the District of Delaware. (2018). iCeutica Pty Ltd. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00525.
4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Assignment records for U.S. Patent Nos. 8,337,886 and 8,865,688.
5. 21 U.S.C. § 355.
6. 35 U.S.C. § 271(e)(2).